Treatment of haemorrhage with transfusion preparations and blood derivatives
Authors:
A. Buliková; M. Matýšková; M. Penka
Authors place of work:
Oddělení klinické hematologie FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Miroslav Penka, CSc.
Published in the journal:
Vnitř Lék 2008; 54(6): 623-631
Category:
Reviews
Předneseno na XIII. Pařízkových dnech s mezinárodní účastí Diagnostika a léčba krvácení v praxi, konaných v Novém Jičíně ve dnech 15. a 16. 3. 2007.
Summary
Appropriate use of blood components and blood products improved both patients care and use of health care resources. In bleeding and/or risk bleeding situations use of these products is often indicated. The authors summarise different guidelines, experiences, indications and problems in hemotherapy concerning bleeding complications.
Key words:
bleeding - blood components - blood products - indications
Zdroje
1. Schmidt PJ. Hemotherapy: from bloodletting magic to transfusion medicine. Transfusion 2006; 46: 166-168.
2. Goodnough LT, Shander A, Spence R. Bloodless medicine: clinical care without allogeneic blood transfusion. Transfusion 2003; 43: 668-676.
3. Heddle NM, Cook RJ, Webert KE et al. Methodologic issues in use of bleeding as an outcome in transfusion medicine studies. Transfusion 2003; 43: 742-752.
4. Stanworth SJ, Brunskill SJ, Hyde CJ et al. Is fresh frozen plasma clinically effective? A systematic review of radomized controlled trials. Br J Hematol 2004; 126; 139-152.
5. Siegennthaler MA, Schneider PH, Tissott JD. Haemovigilance in a general university hospital: need for a more comprehensive classification and a codification of transfusion-related events. Vox Sanguinis 2005; 88: 22-30.
6. Turek P. Properties of blood components and plasma fractions. In: Heier HE, Turek P, Walterová L (eds). ETSM Residential Course. Clinical transfusion medicine.2006: 19-30.
7. Spence RK. Clinical use of plasma and plasma fractions. Best Pract Res Clin Haematol 2006; 19: 83-96.
8. Murphy MF, Wallington TB. Blood Transfusion Task Force. Guidelines for the clinical use of red cell transfusions. British J Haematol 2001; 113: 24-31.
9. Stainsby D, MacLennan S, Thomas D et al. British Committee for Standards in Haematology. Guidelines on the management of massive blood loss. Br J Haematol 2006; 135: 634-641.
10. van Klei WA, Moons KGM, Rhwinwck Leyaaiua AT et al. A reduction in type and screen: Preoperative prediction of RBC transfusions in surgery procedures with intermediate transfusions risks. Br J Anaesthesia 2001; 87: 250-259.
11. O´Shaughnessy DF, Atterbury C, Maggs PB et al. British Committee for Standards in Hematology, Blood Transfusion Task Force. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 2004; 126: 11-28.
12. Spence RK. Clinical use of plasma and plasma fractions. Best Pract Res Clin Haematol 2006; 19: 83-96.
13. Walterová L. The role of platelets, FFP and coagulation factors. In: Heier HE, Turek P, Walterová L (eds). ETSM Residential Course. Clinical transfusion medicine. Liberec 29. 3.-2. 4. 2006.
.
14. Barnett SL, Cimo M, Matevosyan K et al. Study of coagulation factors in patients with mild prolongation of prothrombin time. Implication for neurosurgical patients. Neurosurgery 2004; 55; 487.
15. Holland LL, Foster TM, Marlar RA et al. Fresh frozen plasma is ineffective for correcting minimally elevated international normalized ratio. Transfusion 2005; 45: 1234-1235.
16. Abdel-Wahab OI, Healy B, Dzik WH. Effect of fresh-frozen plasma transfusion on prothrombin time and bleeding in patients with mild coagulation abnormalities. Transfusion 2006; 46: 1279-1285.
17. Stanworth SJ, Brunskill SJ, Murphy MF et al. Appraisal of the evidence for the clinical use of FFP and plasma fractions. Best Pract Res Clin Haematol 2006; 19: 67-82.
18. Dzik W, Rao A. Why do physicians request fresh frozen plasma? Transfusion 2004; 44: 1393-1394.
19. Palo R, Capraro L, Hovilehto S et al. Population-based audit of fresh-frozen plasma transfusion practices. Transfusion 2006; 46: 1921-1925.
20. Levi M, de Jonge E, van der Poll T. Plasma and plasma components in the management of disseminated intravascular coagulation. Best Pract Res Clin Haematol 2006; 19: 127-142.
21. Erber WN, Perry DJ. Plasma and plasma products in the treatment of massive haemorrhage. Best Pract Res Clin Haematol 2006; 19: 97-112.
22. Hardy JF, de Moerloose P, Samama CM. The coagulopathy of massive transfusion. Vox Sanguinis 2005; 89: 123-127.
23. Weippert-Kretschmet M, Karger R, Kretscher V. Peri-operative/post-traumatic haemostatic disorders: therapy. In: Heier HE, Turek P, Walterová L (eds). ETSM Residential Course. Clinical transfusion medicine. Liberec 29. 3.-2. 4. 2006: 145-152.
24. Isaacs MS, Scheuermaier KD, Levy BL at al. In vitro efects of thawing fresh-frozen plasma at various temperatures. Clin Appl Thromb/Hemost 2004; 10: 143-148.
25. Gumulec J, Kesseler P, Penka M et al. Krvácivé komplikace při léčbě warfarinem. Vnitř Lék 2006; 52: 79-95.
26. Penka M, Buliková A, Gumulec J et al. Příprava nemocných na dlouhodobé antikoagulační léčbě kumariny k invazivním zákorkům. Vnitř Lék 2006; 52(Suppl 1): 35-40.
27. Bulik O. Extrakce zubů a antikoagulační terapie-srovnání různých postupu. Prakt Zubn Lek 2004; 52; 68-77.
28. Ansell J, Hirsh J, Poller H et al. The pharmacology and management of the vitamin K antagonists. Chest 2004; 2004: 204S-233S.
29. Baglin TP, Keeling DM, Watson HG. Guidelines on oral anticoagulation (warfarin): third edition - 2005 update. Br J Haematol 2005; 132: 277-285.
30. Ramsey G. Treating coagulopathy in liver disease with plasma transfusions or recombinant factor VIIa: an evidence-based review. Best Pract Res Clin Haematol 2006; 19: 113-126.
31. Deitcher SR. Interpretation of the INR in patients with liver disease. Lancet 2002; 359: 47-48.
32. McCullough J. Current issues with platelet transfusion in patients with cancers. Semin Hematol 2000; 37(Suppl 4): 3-10.
33. Arnold DM, Crowther MA, Cook RJ et al. Utilisation of platelet transfusion in the intensive care unit: indications, transfusion triggers, and platelet count responses. Transfusion 2006; 46: 1286-1291.
34. Greeno E, McCullough G, Weinsdorf D. Platelet utilization and the transfusion trigger: a prospective analysis. Transfusion 2007; 47: 201-205.
35. Cameron B, Rock G, Olberg B et al. Evaluation of platelet transfusion trigger in a tertiary-care hospital. Transfusion 2007; 47: 206-211.
36. Corash L. How much do we know about the platelet transfusion threshold? Transfusion 2003; 43: 691-693.
37. British committee of standards in haematology, blood transfusion task force: Guideline for the use of platelet transfusion. Br J Haematol 2003; 122: 10-23.
38. Lasota Z, Gumulec J, Janek D et al. Substituční hemoterapie. Doporučení pro klinickou praxi v zařízeních EUROMEDNET [online]. Dostupné z
39. Brand A. Transfusion support in malignant diseases. In: Heier HE, Turek P, Walterová L (eds). ETSM Residential Course. Clinical transfusion medicine. Liberec 29. 3.-2. 4. 2006: 67-75.
40. Feies D, Innerhofer P, Schobersberg W. Coagulation management in trauma patients. Curr Opin Anaestesiol 2002; 15: 217-223.
41. Bátorová A, Horváthová D, de Moerloose P et al. Fenotypová a genotypová analýza vrodenej hypofibrinogenémia a dysfibrinogenémie. Vnitř Lék 2005; 51: 802-808.
42. Fries D, Krismer A, Klinger A et al. Effect of fibrinogen on reversal of dilutional coagulaopahty: a porcine model. Br J Anaestesia 2005; 95: 172-178.
43. Charbit B, Mandelbrot L, Samain E et al. The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage. J Thromb Haemost 2006; 5: 266-273.
44. Lorenz R, Kiencast J, Otto U et al. Efficacy and safety of a prothrombin complex concentrate with two virus-inactivation steps in patients with severe liver damage. Eur J Gastrenterol Hepatol 2003; 15: 15-20.
45. Lankiewitz MW, Hays J, Friedman KD et al. Urgent reversal of warfarin prothrombin complex concentrate. J Thromb Haemost 2005; 4: 967-970.
46. Dusel CHH, Grundmann C, Eich S et al. Identification of prothrombin as a major thrombogenic agent in prothrombin complex concentrates. Blood Coagul Fibrinolysis 2004; 15: 405-411.
47. Matýšková M. Poruchy krevního srážení. In: Penka M, Buliková A, Matýšková M et al. Hematologie. Praha: Grada Publishing 2001: Vol. 1, 131-166.
48. Hedner U, Kiesel W. Use of human factor VIIa in the treatment of two hemofilie A patients with high-titer inhibitors. J Clin Invest 1998; 71: 1836-1841.
49. Roberts HR, Monroe DM, White GC. The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood 2004; 104: 3858-3064.
50. Mathew P, Simon TL, Hunt KE et al. How we manage request for recombinant factor VIIa (NovoSeven). Transfusion 2007; 47: 8-14.
51. Levi M. Recombinant factor FVIIa: a general hemostatic agent? Not yet. J Thromb Haemost 2004; 2: 1695-1697.
52. Roberts HR. Recombinant hemostatic agent? J Thromb Haemost 2004; 2: 1691-1694.
53. Černý V, Cvachovec K, Kasal E et al. Zásady podpory koagulace u život ohrožujícího a neztišitelného krvácení. Anest Inten Med 2005; 6: 314-315.
Štítky
Diabetology Endocrinology Internal medicineČlánok vyšiel v časopise
Internal Medicine
2008 Číslo 6
Najčítanejšie v tomto čísle
- Treatment of haemorrhage with transfusion preparations and blood derivatives
- Late recurrences of atrial fibrillation in patients after direct-current cardioversion
- Imaging of stenosis of ramus interventricularis anterior by computed tomography and selective coronarography
- Cancer personality: Current view and implications for future research